Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
LYRA THERAPEUTICS INC (LYRA)
OTCHealth CareBiotechnologySnapshot 2026-11-05
$0.190.00%
Close 2026-11-05 · 1-day change
OTCHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LYRA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Implement cost reduction plan including workforce cuts and lease terminations | A primary condition in LYRA THERAPEUTICS INC's published investment case. The stated target is Successful execution of cost reduction plan by end of 2026. | Improving | Failure to reduce costs or terminate leases as planned by FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making healthcare business rather than an established, steady compounder. The long-term thesis is marked intact, though the latest signal has turned cautious and confidence is only medium.
The valuation evidence points to LYRA being cheap versus peers, while the model has low confidence and the expectations gap is negative. The priced-in assessment is tagged justified, with low fragility, so the evidence does not show that market expectations are unusually fragile.
Recent financial performance is described as neutral and in the top half of its industry, but LYRA remains loss-making. Management priorities, including suspending LYR-210 development and cutting costs, have mixed status; recent merger agreement terminations and a listing-rule notice add near-term concerns.
Near term, a guidance cut or further weakening in jobs data could add pressure, while continued strong results and guidance from healthcare peers could support sector momentum. Over the multi-year view, the thesis depends on whether cost actions and other management priorities progress while the business improves its financial footing.
The 1-3 year view is intact but cautious: relative industry performance offers some support, while losses, high risk, and mixed execution leave the case uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Suspend development of lead product LYR-210 |
| A primary condition in LYRA THERAPEUTICS INC's published investment case. The stated target is No further development of LYR-210 through 2026. |
| Intact |
| Resumption of LYR-210 development or increased spending on it |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue decline stabilizes and does not worsen beyond consensus | A primary condition in LYRA THERAPEUTICS INC's published investment case. The stated target is Revenue decline less severe than -60% YoY in next 12 months. | Intact | Revenue decline worse than -60% YoY next 4 quarters | Revenue growth: -96.65% FY2025-Q4; GAAP. Published target: Revenue decline less severe than -60% YoY in next 12 months. Target period is not explicitly aligned with this observation. Mar 31, 2026-96.650718 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-7.07 → $-7.07 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-07-25 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-07-26 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-07-27 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-07-28 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-07-29 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-07-30 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-07-31 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-01 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-02 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-03 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-04 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-05 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-06 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-07 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-08 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-09 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-10 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-12 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-13 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-14 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-15 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-16 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-17 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-18 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-19 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-20 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-21 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-22 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-23 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-24 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-25 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-26 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-27 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-28 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-29 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-30 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-08-31 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-01 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-02 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-03 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-04 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-05 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-06 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-07 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-08 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-09 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-10 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-11 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-12 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-13 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-14 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-15 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-16 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-17 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-18 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-19 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-20 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-21 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-22 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-23 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-24 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-25 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-26 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-27 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-28 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-29 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-09-30 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-01 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-02 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-03 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-04 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-05 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-06 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-07 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-08 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-09 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-10 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-11 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-12 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-13 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-14 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-15 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-16 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-17 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-18 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-19 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-20 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-21 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-22 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-23 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-24 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-25 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-26 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-27 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-28 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-29 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-30 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-10-31 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-11-01 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-11-02 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-11-03 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-11-04 | $-7.07 | $5,732,500 | 1 / 1 |
| 2026-11-05 | $-7.07 | $5,732,500 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.